38. GAMIDA-CELL: www.gamida-cell.com

Gamida Cell Ltd. is a leader in the clinical development of hematopoietic (blood) stem cell therapeutics for the treatment of cancer as well as future regenerative cell-based medicines for such illnesses as heart disease and neurological disorders. The Company was founded in 1998 based on technology for stem cell expansion licensed from Hadassah University Medical Center, Jerusalem, Israel.

The combined market potential of Gamida Cell’s expanded stem cell products is estimated at $30 billion worldwide. This includes products derived from umbilical cord blood stem cells as well as stem cells from bone marrow and peripheral blood. Gamida Cell expects to continue its leadership role in the stem cell arena, launch a product in the stem cell hematopoietic transplant market, and achieve high profit margins and sales even with future competitors in the market. The market launch for the Company’s first commercial product, StemEx®, is anticipated for 2009. In March 2005, StemEx® was granted an FDA orphan drug designation.

Yael Margolin, President & CEO

Gamida Cell Ltd. Cell Therapy Technologies
PO Box 34670
Jerusalem 91340
Israel

Press and IR contact:
Marjie Hadad
marjie@gamida-cell.com
+972-54-536-5220